AB Pharma was a High-tech Enterprise founded by Dr. Zhan, a special expert of the National "Thousand people Plan". AB Pharma is located inShanghai Xinzhuang Industrial Zone, and mainly dedicated to the research and development of innovative drugs, especially focused on the critical diseases at home and abroad thatinvolves in large population and increasing incidence. At present, AB Pharma is focusing on the fields of anti-HCV, anti-tumor, endocrine, and has owned a number of global independent intellectual property rights.

At present, AB pharma has successfully developed the " all-genotypes efficient new drugs (ZN2007 and ZN6168) with double targets (NS3/4A and NS5A) against hepatitis C virus (HCV)", and is doing the clinical trials. AB Pharma’s  all-genotypes efficient new drugs of HCV and their combination therapy have been selected into the "National 13th Five-Year Major New Drug Creation Special Project".The clinical trials are being moved forward, and all clinical trials are expected to be completed around the end of 2020 that we hope to provide effective treatment for thousands of patientsas soon as possible. In addition, the self-developed innovative drugs in the field of tumor and endocrine have made breakthroughs so far, and it is expected to enter clinical trials at home and abroad around the end of 2019.

From the beginning of its establishment, AB Pharma has paid lots of attention to R & D investment and the staff training. At present, we have a high quality R & D and management team, which has laid a solid foundation in the field of innovative medicine and is the core guarantee of the company's sustainable development.

021-5442 6122
©2018 AB Pharma Ltd. All rights reserved
沪公网安备 33311802006333号 沪ICP备13019832号-1
Technical Support:www.51eway.com
No. 99, Lane 133, Guangzhong Road, Shanghai